First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study

The choice of first-line biologic is highly impacting UC outcome and cannot be fully compensated by later treatments, advocating for the use of the most effective therapeutic option as first-line biologic.